A call for transparency, improved reporting, and interpretation of trials using surrogate end points in cardiac electrophysiology

By afschroeder • August 3, 2025

Tereshchenko LG, Manyara AM, Ciani O, Sodeke SO, Bradford CN, Santangeli P, Kapadia SR, Wazni O, Narayan SM, Chugh SS, Bilchick K, Huizar JF, Vaseghi M, Chung MK, Ellenbogen KA, Taylor RS. A call for transparency, improved reporting, and interpretation of trials using surrogate end points in cardiac electrophysiology. Heart Rhythm. 2025 Aug;22(8):e492-e499. doi: 10.1016/j.hrthm.2025.02.038. Epub 2025 Feb 26. PMID: 40021073; PMCID: PMC12317828.

Tags: Biomarker, Cardiology/Epi, Cedars Sinai DoM, Checklist, Clinical Trial, Outcome, Publications, Randomized Controlled Trial, Research design, standards, Surrogate end point, surrogate marker

Emerging quantitative CCTA imaging biomarkers for cardiovascular risk stratification: a narrative review

Mora R, Irannejad K, Abbas N, Mogga P, Iskander B, Hubbard L, Roy S, Lakshmanan S, Budoff M, Krishnan S. Emerging quantitative CCTA imaging biomarkers[...]

Cardiovascular Toxicity of Antibody-Drug Conjugates in Breast Cancer: Current Evidence and Evolving Considerations: JACC: CardioOncology Primer

Moore H, Huppert LA, Moslehi JJ, Yang EH, Hatcher S, Thomas A. Cardiovascular Toxicity of Antibody-Drug Conjugates in Breast Cancer: Current Evidence and Evolving Considerations:[...]

Association between depressive symptoms and thoracic aortic calcification, and their independent and joint prognostic value for incident atherosclerotic cardiovascular disease in the MESA cohort

Arai D, White Q, Ichikawa K, McClelland RL, Johnson WC, Yabuki M, Hansen S, Budoff MJ. Association between depressive symptoms and thoracic aortic calcification, and[...]